Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Luis López Lázaro's publication output changed over time?
ScholarIQpublication output · 1999–2025
Output grew0% over the shown period — from 1 works in 1999 to 1 in 2025.
1
2
1
2
2
2
1
1999200020012002200320052025
What are the most-cited papers on Luis López Lázaro?
ScholarIQmost cited works
Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors
A. Taamma, J. L. Misset, M. Riofrio, C. Guzmán, Étienne Brain, Luis López Lázaro, Hilde Rosing, José Jimeno, Esteban Cvitkovic
Journal of Clinical Oncology. 2001160 Citations
Erythema nodosum: Etiologic and predictive factors in a defined population
Carlos Garcı́a-Porrúa, Miguel Á. González‐Gay, Manuel Vázquez‐Caruncho, Luis López Lázaro, Mercedes Lueiro, María Lameiras Fernández, Javier Alvarez‐Ferreira, Ramón M. Pujol
S132787887. 2000153 Citations
Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients With Advanced Malignancies
Sandrine Faivre, Stéphanie Chièze, Catherine Delbaldo, Nora Ady-vago, Cecilia Guzmán, Luis López Lázaro, Stéphanie Lozahic, José Jimeno, Fernando Pico, Jean Pierre Armand, José A. López-Martín, Éric Raymond
Journal of Clinical Oncology. 200599 CitationsOPEN ACCESS
Yondelis® (trabectedin, ET-743): the development of an anticancer agent of marine origin
Ch. van Kesteren, M. M. M. de Vooght, Luis López Lázaro, Ron A. A. Mathôt, Jan H.M. Schellens, José Jimeno, Jos H. Beijnen
S158028025. 200387 Citations
Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer
Jeany M. Rademaker-Lakhai, Simon Horenblas, W. Meinhardt, Ellen Stokvis, Theo M. de Reijke, José Jimeno, Luis López Lázaro, José A. López-Martín, Jos H. Beijnen, Jan H.M. Schellens
Clinical Cancer Research. 200587 Citations
Related on ScholarIQ
Swedish Orphan Biovitrum (United States)
Institution
Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors
Paper
Erythema nodosum: Etiologic and predictive factors in a defined population
Paper
Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients With Advanced Malignancies
Paper
Yondelis® (trabectedin, ET-743): the development of an anticancer agent of marine origin
Paper
Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer
Paper